{"drugs":["Altretamine","Hexalen"],"mono":[{"id":"20950-s-0","title":"Generic Names","mono":"Altretamine"},{"id":"20950-s-1","title":"Dosing and Indications","sub":[{"id":"20950-s-1-4","title":"Adult Dosing","mono":"<b>Ovarian cancer, Persistent or recurrent disease; monotherapy as second-line after cisplatin or alkylating agent-based combination:<\/b> 260 mg\/m(2)\/day ORALLY in 4 divided doses (after meals and at bedtime) for 14 or 21 consecutive days per 28 day cycle "},{"id":"20950-s-1-5","title":"Pediatric Dosing","mono":"safety and effectiveness in children have not been established"},{"id":"20950-s-1-6","title":"Dose Adjustments","mono":"<ul><li><b>gastrointestinal intolerance:<\/b> (unresponsive to symptomatic measures) temporarily discontinue for 14 days or longer; restart at 200 mg\/m(2)\/day<\/li><li><b>myelosuppression:<\/b> (WBC count less than 2,000\/mm(3), granulocyte count less than 1,000\/mm(3), OR platelet count less than 75,000\/mm(3)) temporarily discontinue for 14 days or longer; restart at 200 mg\/m(2)\/day<\/li><li><b>neurotoxicity, progressive:<\/b> temporarily discontinue for 14 days or longer; restart at 200 mg\/m(2)\/day; discontinue indefinitely if neurologic symptoms do not stabilize<\/li><\/ul>"},{"id":"20950-s-1-7","title":"Indications","mono":"<b>FDA-Labeled Indications<\/b><br\/>Ovarian cancer, Persistent or recurrent disease; monotherapy as second-line after cisplatin or alkylating agent-based combination<br\/><b>Non-FDA Labeled Indications<\/b><ul><li>Breast cancer<\/li><li>Colon cancer<\/li><li>Endometrial carcinoma<\/li><li>Malignant epithelial tumor of ovary<\/li><li>Malignant lymphoma<\/li><li>Multiple myeloma<\/li><li>Small cell carcinoma of lung<\/li><\/ul>"}]},{"id":"20950-s-2","title":"Black Box Warning","mono":"<b>Oral (Capsule)<\/b><br\/>Peripheral blood counts should be monitored at least monthly, prior to the initiation of each course of altretamine, and as clinically indicated. Because of the possibility of altretamine-related neurotoxicity, neurologic examination should be performed regularly during altretamine administration.<br\/>"},{"id":"20950-s-3","title":"Contraindications\/Warnings","sub":[{"id":"20950-s-3-9","title":"Contraindications","mono":"<ul><li>hypersensitivity to altretamine<\/li><li>preexisting severe bone marrow depression or severe neurologic toxicity<\/li><\/ul>"},{"id":"20950-s-3-10","title":"Precautions","mono":"<ul><li>concurrent administration of MAO inhibitor class antidepressants; may cause severe orthostatic hypertension<\/li><li>concomitant administration of cimetidine not recommended<\/li><li>concomitant administration of pyridoxine; adversely affects response duration<\/li><\/ul>"},{"id":"20950-s-3-11","title":"Pregnancy Category","mono":"<ul><li>D (FDA)<\/li><li>D (AUS)<\/li><\/ul>"},{"id":"20950-s-3-12","title":"Breast Feeding","mono":"Micromedex: Infant risk cannot be ruled out.<br\/>"}]},{"id":"20950-s-4","title":"Drug Interactions","sub":[{"id":"20950-s-4-13","title":"Contraindicated","mono":"<ul>Rotavirus Vaccine, Live (established)<\/ul>"},{"id":"20950-s-4-14","title":"Major","mono":"<ul><li>Adenovirus Vaccine Type 4, Live (established)<\/li><li>Adenovirus Vaccine Type 7, Live (established)<\/li><li>Bacillus of Calmette and Guerin Vaccine, Live (established)<\/li><li>Brofaromine (probable)<\/li><li>Clorgyline (probable)<\/li><li>Furazolidone (probable)<\/li><li>Influenza Virus Vaccine, Live (established)<\/li><li>Iproniazid (probable)<\/li><li>Isocarboxazid (probable)<\/li><li>Lazabemide (probable)<\/li><li>Linezolid (probable)<\/li><li>Measles Virus Vaccine, Live (established)<\/li><li>Moclobemide (probable)<\/li><li>Mumps Virus Vaccine, Live (established)<\/li><li>Nialamide (probable)<\/li><li>Pargyline (probable)<\/li><li>Phenelzine (probable)<\/li><li>Poliovirus Vaccine, Live (established)<\/li><li>Procarbazine (probable)<\/li><li>Pyridoxine (probable)<\/li><li>Rasagiline (probable)<\/li><li>Rubella Virus Vaccine, Live (established)<\/li><li>Selegiline (probable)<\/li><li>Smallpox Vaccine (established)<\/li><li>Toloxatone (probable)<\/li><li>Tranylcypromine (probable)<\/li><li>Typhoid Vaccine (established)<\/li><li>Varicella Virus Vaccine (established)<\/li><li>Yellow Fever Vaccine (established)<\/li><\/ul>"}]},{"id":"20950-s-5","title":"Adverse Effects","mono":"<b>Common<\/b><ul><li><b>Endocrine metabolic:<\/b>Alkaline phosphatase raised (9%)<\/li><li><b>Gastrointestinal:<\/b>Nausea and vomiting (mild-to-moderate, up to 70%; (Blac, 1980); severe, 1%)<\/li><li><b>Hematologic:<\/b>Anemia (33%), Leukopenia (5%), Thrombocytopenia (9%)<\/li><li><b>Neurologic:<\/b>Peripheral nerve disease (up to 31%)<\/li><li><b>Renal:<\/b>Serum blood urea nitrogen raised (9%), Serum creatinine raised (7% to 20%)<\/li><li><b>Other:<\/b>Fatigue (7% (grade 3))<\/li><\/ul><b>Serious<\/b><ul><li><b>Hematologic:<\/b>Myelosuppression<\/li><li><b>Neurologic:<\/b>Neurotoxicity, Seizure (1%)<\/li><\/ul>"},{"id":"20950-s-6","title":"Drug Name Info","sub":{"0":{"id":"20950-s-6-17","title":"US Trade Names","mono":"Hexalen<br\/>"},"2":{"id":"20950-s-6-19","title":"Class","mono":"Antineoplastic Agent<br\/>"},"3":{"id":"20950-s-6-20","title":"Regulatory Status","mono":"RX<br\/>"},"4":{"id":"20950-s-6-21","title":"Generic Availability","mono":"No<br\/>"}}},{"id":"20950-s-7","title":"Mechanism Of Action","mono":"Systemic: The exact mechanism of action is unknown . Although altretamine structurally resembles an alkylating agent, it has not been found to have alkylating activity  in vitro    . There is some evidence that it may inhibit DNA and RNA synthesis .<br\/>"},{"id":"20950-s-8","title":"Pharmacokinetics","sub":{"0":{"id":"20950-s-8-23","title":"Absorption","mono":"Systemic: Rapidly absorbed <br\/>"},"2":{"id":"20950-s-8-25","title":"Metabolism","mono":"Systemic: Hepatic <br\/>"},"3":{"id":"20950-s-8-26","title":"Excretion","mono":"Systemic: Renal: &lt;1%  unchanged<br\/>"}}},{"id":"20950-s-9","title":"Administration","mono":"<ul><li><b>General Information<\/b><br\/>use proper procedures for handling and disposal of chemotherapy<br\/><\/li><li><b>Oral<\/b><br\/>take doses after meals and at bedtime<br\/><\/li><\/ul>"},{"id":"20950-s-10","title":"Monitoring","mono":"<ul><li>evidence of tumor response<\/li><li>peripheral blood counts; at least monthly, prior to initiating each course<\/li><li>neurologic examinations; prior to initiating each course<\/li><li>signs and symptoms of myelosuppression<\/li><\/ul>"},{"id":"20950-s-11","title":"How Supplied","mono":"<b>Hexalen<\/b><br\/>Oral Capsule: 50 MG<br\/>"},{"id":"20950-s-12","title":"Toxicology","sub":[{"id":"20950-s-12-31","title":"Clinical Effects","mono":"<b>ALTRETAMINE<\/b><br\/>OVERDOSE: No data available. ADVERSE EFFECTS: Dose-limiting toxicities include nausea, vomiting, diarrhea, abdominal pain and neuropathy. Dose-related myelosuppression has occurred rarely with therapy.<br\/>"},{"id":"20950-s-12-32","title":"Treatment","mono":"<b>ALTRETAMINE <\/b><br\/><ul><li>Decontamination: Activated charcoal, gastric lavage.<\/li><li>Support: Treatment is symptomatic and supportive.<\/li><li>Colony stimulating factor: Filgrastim for severe granulocytopenia: 5 mcg\/kg\/day IV infusion or subQ<\/li><li>Monitoring of patient: Monitor CBC, renal function and hepatic enzymes, electrolytes and fluid status.<\/li><li>Pyridoxine: Used to prevent peripheral neuropathy with therapeutic use; no experience in overdose.<\/li><\/ul>"},{"id":"20950-s-12-33","title":"Range of Toxicity","mono":"<b>ALTRETAMINE<\/b><br\/>THERAPEUTIC: 260 mg\/m(2)\/day divided in 4 doses, daily for 14 to 21 days. TOXICITY: Not established.<br\/>"}]},{"id":"20950-s-13","title":"Clinical Teaching","mono":"<ul><li>This drug may cause diarrhea, nausea, vomiting, or peripheral neuropathy.<\/li><li>Instruct patient to report signs\/symptoms of neurotoxicity or myelosuppression.<\/li><li>Patient should take doses after meals and at bedtime.<\/li><li>Advise patient on the proper handling and disposal of chemotherapy drugs.<\/li><li>Advise patient to avoid vaccines during therapy due to drug-induced immunosuppression.<\/li><li>Avoid concomitant pyridoxine (vitamin B6), cimetidine, and MAO-type antidepressants.<\/li><li>Avoid concomitant pyridoxine (vitamin B6), cimetidine, and MAO-type antidepressants.<\/li><\/ul>"}]}